Research Paper Volume 13, Issue 23 pp 25304—25324

GDI2 is a novel diagnostic and prognostic biomarker in hepatocellular carcinoma


Figure 6. Prognostic impact of clinical subtypes associated with GDI2 expression in HCC patients. (AI) High GDI2 expression was associated with poor outcomes on overall survival (OS) in HCC patients of a TCGA cohort with clinicopathological indicators as: (A) Age>60; (B) BMI>25; (C) AFP(ng/ml)<=400; (D) T1 Stage; (E) N0 Stage; (F) M0 Stage; (G) Fibrosis ishak score-1/2&3/4&5/6; (H) Pathologic Stage I&II; and (I) No Vascular invasion. Blue: high GDI2; Red: low GDI2. *P < 0.05,**P < 0.01. (J) Forest map illustrated subtypes of clinicopathological features associated with GDI2 expression for HCC prognosis. *P < 0.05,**P < 0.01.